RxDoctor Payments Data

Paulette Lewis, MD

Internal Medicine · Horseheads, NYNPI 1851362594

Payments from drug & device makers

$2,956in general payments, 2019–2025

Across 154 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$686
  • AbbVie$684
  • AstraZeneca$638
  • Pfizer$475
  • GSK$155
  • Boehringer Ingelheim$73
  • plus $245 from 6 others

What the payments were for

  • Food & beverage$2,956100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,956 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$113,922
Medicare patients
359
Services billed
1,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide144$294,232
EliquisApixaban87$101,215
FarxigaDapagliflozin Propanediol58$88,443
TrulicityDulaglutide45$78,536
JanuviaSitagliptin Phosphate51$66,879
XareltoRivaroxaban36$51,903
JardianceEmpagliflozin38$51,818
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$32,843
ArexvyRsvpref3 Antigen/As01e/Pf61$18,782
EntrestoSacubitril/Valsartan21$18,737
Budesonide ErBudesonide12$17,774
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,279
Advair HfaFluticasone Propion/Salmeterol16$9,980
Spiriva RespimatTiotropium Bromide16$8,849
Breo ElliptaFluticasone/Vilanterol14$8,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$686$294,232144 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$638$103,56285 claims
PfizerEliquis$475$101,21587 claims
Lilly USA, LLCTrulicity$68$78,53645 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Arnuity Ellipta$155$64,158113 claims
Boehringer IngelheimJardiance, Spiriva Respimat$73$60,66754 claims
AbbVieSynthroid$684$3,82161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Horseheads

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →